Stock News and Filings Feed


Add CDY
to your dashboard

1
share
Cellmid secures new US partner for hair products

2017-08-03 proactiveinvestors.com.au
Cellmid (ASX:CDY) has secured a new partnership in the U.S. with premium retailer Neiman Marcus for its evolis® Professional products.

7
shares
Cellmid receives China import permit for cosmetics

2017-08-01 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has had its import permits to China renewed for its for Jo-Ju® and Lexilis® cosmetic products.

1
share
Cellmid Limited gets a boost for its midkine assets

2017-07-03 proactiveinvestors.com.au
Cellmid Limited (ASX:CDY) has had results from a melanoma study related to midkine published by the prestigious and renowned journal, Nature.

Cellmid's Maria Halasz lifts stake on-market

2017-06-06 proactiveinvestors.com.au
Cellmid's (ASX:CDY) chief executive officer, Maria Halasz, has lifted her stake in the company through an on-market purchase.

1
share
Cellmid achieves record quarterly sales for hair loss products

2017-04-19 proactiveinvestors.com.au
Cellmid (ASX:CDY) has achieved record sales of $1.51 million for the March quarter, up 120% from the same period last year.

Cellmid's Maria Halasz buys shares on market

2017-03-16 proactiveinvestors.com.au
Cellmid (ASX:CDY) has had its managing director and CEO, Maria Halasz, purchase 400,000 shares on market recently.

Cellmid has hair loss technology published in journal

2017-03-02 proactiveinvestors.com.au
Cellmid (ASX:CDY) has had its FGF5 inhibitory hair loss technology published in a peer reviewed journal known as Clinical, Cosmetic, and Investigational Dermatology.

Cellmid bulks up research and development financing

2017-03-02 proactiveinvestors.com.au
Cellmid (ASX:CDY) has refinanced its $700,00 research and development loan agreement from February 2016 with a new larger $2 million facility.

8
shares
Cellmid receives patent for midkine treatment in Europe

2017-02-07 proactiveinvestors.com.au
Cellmid's (ASX:CDY) patent for midkine (MK) treatment of alopecia has been allowed by the European Patent Office.

4
shares
Cellmid gets green light for hair loss patent in U.S.

2017-01-31 proactiveinvestors.com.au
Cellmid (ASX:CDY) has been issued a notice of allowance for a patent entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” by the U.S. Patent and Trademark Office.

Cellmid gets government backing for midkine research program

2017-01-18 proactiveinvestors.com.au
Cellmid (ASX:CDY) has received two Australian government grants totalling $100,000 to support research testing of its midkine (MK) antibodies for use in treatments.

Cellmid's Maria Halasz lifts stake with on-market purchase

2017-01-18 proactiveinvestors.com.au
Halasz purchased 350,000 for $9,124, increasing her direct position to 2.85 million shares (and 12 million loan shares), with her indirect position remaining at circa 12.5 million shares and 5 million unlisted options.

Cellmid expecting royalty payments from midkine license

2016-12-12 proactiveinvestors.com.au
Cellmid (ASX:CDY) to date has derived over $1.2 million from the midkine diagnostics license it issued to New Zealand based Pacific Edge in 2010.

6
shares
Cellmid Ltd receives tax credit to bolster cash position

2016-11-29 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has received $831,000 from the Australian Taxation Office under the research and development tax incentive scheme for the 2016 financial year.

1
share
Cellmid Ltd launches hair loss products into US$3.5B market

2016-11-03 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has launched its lead revenue driving évolis® hair loss products into the U.S. market.

3
shares
Cellmid Ltd secures funds to launch hair loss product in U.S.

2016-11-01 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has received commitments to raise $3 million through the placement of shares to sophisticated and institutional investors priced at $0.03.

1
share
Cellmid Ltd to update on capital raising

2016-10-28 proactiveinvestors.com.au
The ASX has granted more time in the form on a voluntary suspension, following a trading halt.

Cellmid Ltd to reveal raising

2016-10-25 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has been granted a trading halt by the ASX, pending details of a capital raising.

1
share
Cellmid's Maria Halasz increases stake

2016-10-18 proactiveinvestors.com.au
Halasz acquired on-market 290,000 shares for a consideration of $9,860, and exercised 1.5 million listed options for a consideration of $51,000.

Cellmid has record September quarter sales from hair loss products

2016-10-10 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has recorded over $1 million in sales for its hair loss products during the September quarter for the first time ever.

Cellmid Ltd gets boost from study results treating brain cancer

2016-10-07 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) has received results from a pre-clinical collaboration with Complutense University in Spain that suggests the company’s midkine antibodies can be used to treat a type of brain cancer. Cellmid has two business segments, consumer health, which sells products and its midkine (MK) portfolio, which it is looking to clinically develop. Results from this study show that MK antibodies reduce certain brain tumour sizes in animals.

1
share
Cellmid Ltd gets boost from study results treating brain cancer

2016-10-05 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) is an Australian biotechnology company with lead drug candidates in oncology. It also has a revenue generating consumer health division.

Cellmid Ltd gets green light for patent in Europe

2016-09-22 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) is an Australian biotechnology company with lead drug candidates in oncology. It also has a revenue generating consumer health division.

17
shares
Cellmid Ltd's Maria Halasz lifts stake with on-market trade

2016-09-20 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) is an Australian biotechnology company with lead drug candidates in oncology. It also has a revenue generating consumer health division.

Cellmid Ltd: New research shows midkine antibody restores bone loss

2016-08-09 proactiveinvestors.com.au
Cellmid Ltd (ASX:CDY) is an Australian biotechnology company with lead drug candidates in oncology. It also has a revenue generating consumer health division.

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!